Sentetik kannabinoid kullanımı olan bir olguda pregabalin bağımlılığı

Sentetik kannabinoid kullanımı olan bir olguda pregabalin bağımlılığıPregabalin nöropatik ağrı ve parsiyel nöbetlerin tedavisi için onaylanmış bir gama-aminobutirik asit (GABA) analogudur. Pregabalin seçici voltaja duyarlı kalsiyum kanallarının alfa 2 delta alt ünitesine bağlanır. Böylece eksitatör nöro-transmitter salınımını inhibe ederken nöronal GABA düzeylerini artırır. Pregabalinin aynı zamanda Yaygın Anksiyete Bozukluğu'nun tedavisinde kullanımı Avrupa İlaç Komisyonu tarafından onaylanmıştır. Pregabalinin anksiyolitik etkisi benzodiazepinlerin etkisine benzer ve uygulamadan sonra hızla ortaya çıkar. Ancak, Amerika Gıda ve İlaç Dairesi (FDA) ile Avrupa Tıbbi Ürünler Ajansı (EMA) tarafından "Kontrollü Kullanılması Gereken Maddeler V" listesine alınmıştır. Bu, pregabalinin benzodiazepinler gibi kötüye kullanılma potansiyeli düşük olan ilaçlar arasında kabul edildiği anlamına gelmektedir

Pregabalin Addiction in a Case with Synthetic Cannabinoid Use

Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse

PDF

___

1. https://www.drugs.com/schedule-5-drugs.html. Accessed February 28, 2017.
2. Stahl SM. Stahl’s Essential Psychopharmacology. Tunc Alkin (Translation Editor) Fourth ed., Istanbul: Istanbul Tip Kitabevi, 2015; 71-72. (Turkish)
3. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110:628-638. [CrossRef]
4. Jensen TS. Finnerup NB. Management of neuropathic pain. Curr Opin Support Palliat Care 2007; 1:126-131. [CrossRef]
5. Derry S, Cording M, Wiffen PJ , S Law, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. http://onlinelibrary. wiley.com/doi/10.1002/14651858.CD011790.pub2/full. Accessed February 28, 2017.
6. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014; 5:38-56. [CrossRef]
7. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62:1022- 1030. [CrossRef]
8. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014; 28:835-854. [CrossRef]
9. Center for Drug Evaluation and research, U.S. Food and Drug Administration Medical Review (internet) In: Lyrica (pregabalin) capsules. Company: Pfizer, Inc. Aplication No:21-446. https:// www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf. Accessed February 28, 2017.
10. European Medicines Agency. http://www.ema.europa.eu/docs/ en_GB/document. Accessed February 28, 2017.
11. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010; 167:869. [CrossRef]
12. Filipetto FA, Zipp CP, Coren J. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 2010; 110:605-607.
13. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations and possible association with myositis: two case reports. J Clin Psychopharmacol 2012; 32:839-840. [CrossRef]
14. Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report. Bulletin of Clinical Psychopharmacology 2011; 21:64-66. [CrossRef]
15. Aldemir E, Altintoprak AE, Coskunol H. Pregabalin dependence: a case report. Turk Psikiyatri Derg 2015; 26:217-220. (Turkish)
16. Bramness JG, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica®) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010; 107:883-886. [CrossRef]
17. Hadley SJ, Mandel FS, Schweizer E. Switching from longterm benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placeco-controlled trial. J Psychopharmacol 2012; 26:461-470. [CrossRef]
18. Oulis P, Kalogerakou S, Anyfandi E, Konstantakopoulos G, Papakosta VM, Masdrakis V, Tsaltas E. Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol 2014; 29:224-229. [CrossRef]
19. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther 2012; 29:947-957. [CrossRef]
20. Sweet AD. Pregabalin abuse and the risk associated for patients with a previous history of substance misuse. J Addict Res Ther 2013; 4:1. [CrossRef]
21. Oguz G, Guven M, Batmaz S. Pregabalin dependence: a case report. Journal of Dependence 2015; 16:160-163. (Turkish)
22. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 2013; 69:2021-2025. [CrossRef]
23. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28:491-496. [CrossRef]
24. Abuse and misuse potential of pregabalin: a review of the clinical evidence 2012. http://www.dpic.org/sites/default/files/ PregabalinAbuse_CADTH_24Apr2012.pdf. Accessed February 28, 2017.
25. Schwan S, Sundstrom A, Sjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010; 66:947-953. [CrossRef]
26. Millar J, Sadasivan S, Weatherup N, Lutton S. Lyrica nightsrecreational pregabalin abuse in an urban emergency department. Emerg Med J 2013; 30:874. [CrossRef]
27. Papazisis G, Tzachanis D. Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther 2014; 52:709-716. [CrossRef]
28. https://www.drugs.com/schedule-5-drugs.html. Accessed February 28, 2017.